Sarepta Complained To Woodcock About Exondys 51 Review Early And Often
Executive Summary
Documents also show that Sarepta officials begged CDER director for approval on multiple occasions prior to the agency's September 2016 decision.
You may also be interested in...
Exondys Revisited? Translarna Brings Efficacy Woes Into US Panel Review
FDA has twice refused to file PTC Therapeutics' NDA for the Duchenne muscular dystrophy treatment because of 'clearly and convincingly negative' pivotal trials and questionable post hoc analyses; sponsor argues ataluren should be afforded the same consideration and flexibility given to Sarepta's DMD drug eteplirsen, which received a controversial accelerated approval.
Moscicki, One Of US FDA's Industry Connections, Moves To PhRMA
One of the faces of FDA's effort to recruit senior leaders from outside its walls has decided to return to industry.
Once More Unto The Breach: PTC's Duchenne Drug Translarna Gets Advisory Cmte.
US FDA's Peripheral and Central Nervous System Drugs Advisory Committee to consider application, which PTC Therapeutics filed over protest.